Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Thermo Fisher earnings rose 91% vs. a year earlier, the best in years.

Thermo Fisher Earnings Growth Is Best In Years, Crushing Views

Shares of Thermo Fisher Scientific Inc. rose 2.3% in premarket trading Wednesday, after the life sciences and laboratory products company reported third-quarter profit and revenue that were well above expectations. Net income grew to $1.93 billion, or $4.84 a share, from $760 million, or $1.88 a share, in the year-ago period.

Thermo Fisher's stock jumps after big profit, revenue beats

WALTHAM, Mass., Oct. 21, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 26, 2020. Third Quarter 2020 Highlights Third quarter revenue increased 36% to $8.52...

Thermo Fisher Scientific Reports Third Quarter 2020 Results

On Wednesday, October 21, Thermo Fisher Scientific (NYSE: TMO) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Thermo Fisher Scientific's Earnings: A Preview

Avalara Inc

DraftKings

Estee Lauder

Nasdaq

Walmart

Texas Instruments

The novel coronavirus has upended the existing economic order. These seven innovative stocks will reap the rewards of these changes.

7 Innovative Stocks That Are Blossoming in 2020

Activision Blizzard

Dick's Sporting Goods

Fortune Brands Home & Security

Taiwan Semiconductor Manufacturing

Zeroing in on companies that not only offer dividends but also consistently increase their payouts seems like a good idea.

Forget Market Volatility With These Dividend Growth Stocks

Applied Materials

CMC Materials Inc

DuPont de Nemours

Nanotech stocks are a representation of massive human and scientific advancement. These five names will get you ahead of this revolution.

5 Nanotech Stocks to Buy for Huge Innovation

CARLSBAD, Calif., Oct. 15, 2020 /PRNewswire/ -- Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. The...

Thermo Fisher Scientific Launches Modular Closed Cell Processing System for Cell Therapy Manufacturing

Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Thermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy?

Thermo Fisher has enjoyed an exceptional year to date, with investors realizing 43% to the upside, on the back of strong fundamental tailwinds.

What A Ride Its Been For Thermo Fisher In 2020 YTD; The Market Supports The Facts

Amazon

PayPal

Take-Two Interactive Software

Williams-Sonoma

Zoom Video

Largely led by growth stocks, the markets have rallied furiously since the March bottoms were hit. These growth names have been at the forefront of the new COVID world, and have kept our world not only afloat, but growing and transitioning to the new normal.

Top Growth Stocks For October

Cellectis SA

Emergent BioSolutions

Vertex Pharmaceuticals

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

WALTHAM, Mass., Oct. 12, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19 Total Antibody ELISA test, and the Thermo Scientific EliA...

Thermo Fisher Scientific Further Expands COVID-19 Test Portfolio with Two New Antibody Tests

In the latest trading session, Thermo Fisher Scientific (TMO) closed at $445.89, marking a -1.06% move from the previous day.

Thermo Fisher Scientific (TMO) Stock Moves -1.06%: What You Should Know

Abbott Labs

Exact Sciences

Hologic

QIAGEN

Given the current testing requirements across the world, the diagnostic testing business for COVID-19 is rapidly evolving.

Coronavirus Drives Testing Stocks: Is There Room for More Upside?

LHC Group

Novocure

Here are three growth stocks from the MedTech space which have maintained stellar performance even during the pandemic-led market meltdown.

3 Growth-Focused MedTech Stocks to Buy Amid the COVID-19 Crisis

Big Lots

Sapiens International

Thor Industries

Stock market volatility and near-zero interest rates have been driving the appeal for dividend investing.

5 Cheap Dividend Growth Stocks to Buy Amid Volatility

Thermo Fisher's (TMO) pharma and biotech end markets register growth on robust performance in bioproduction and pharma services businesses.

Thermo Fisher Rides on End Market Growth, Test Revenues

Agilent Technologies

Danaher

These laboratory equipment suppliers' fate does not depend on the end result of the R&D outcomes of the drug and vaccine makers.

3 Picks to Ride the Coronavirus-Led Strength in Lab Plastic Space

Quest Diagnostics

Labcorp Holdings Inc

Allscripts Healthcare Solutions

PRA Health Sciences

Veeva Systems

Asian countries have already shown clear signs of major economic recession.

Is Another Great Depression Imminent or Is it Just a Myth?

Fresenius Medical Care

Let's grab these three stocks that have continued to show tremendous promise despite market volatility resulting from the coronavirus pandemic.

3 MedTech Outperformers to Grab Amid September Pullback

Thermo Fisher (TMO) consumables already support critical COVID-19 work and include sample collection vials and lab essentials.

Thermo Fisher Expands Lab Plastic Making for Coronavirus Support

Thermo Fisher Scientific (TMO) closed at $433.88 in the latest trading session, marking a -0.28% move from the prior day.

Thermo Fisher Scientific (TMO) Stock Moves -0.28%: What You Should Know

WALTHAM, Mass. , Sept. 15, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Further Expands Laboratory Plastics Production to Support COVID-19 Testing, Therapies and Vaccines

Corporate balance sheets are littered with failed acquisitions, but one company's experiment in buying up smaller competitors is producing great results.

News for Thermo Fisher Scientific Stock (TMO)